 Arcturus Therapeutics Holdings Inc NASDAQ: ARCT shares were retreating sharply Tuesday after the company issued an update on its coronavirus vaccine program. What Happened: San Diego, California-based Arcturus announced interim data for a Phase 12 study of its vaccine candidate ARCT-021 that shows a favorable safety profile and a less favorable immunogenicity data. 